zuma-19: maximizing safety of car t-cell therapy in lbcl
Published 3 years ago • 372 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
2:53
safety and efficacy of allogeneic car-t cell treatment
-
2:23
prognostic value of alc following bcma car t-cell therapy in multiple myeloma
-
2:09
the role of car-t therapy in hematologic malignancies
-
1:16
the efficacy of car t-cell therapy in richter’s transformation
-
3:21
safety management of car-t cell therapy in dlbcl
-
1:59
efficacy and safety of cd19-targeted car t-cells for relapsed/refractory all
-
1:11
safety profile of anti-cd19 car t-cell therapy axicabtagene ciloleucel
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
1:01:36
deciphering car-t cells: exploring functional mechanisms to drive next generation immunotherapy
-
5:04
dlbcl and car t cell therapy - kim's lymphoma story
-
3:00
fhvh-bcma-t car t-cell therapy shows efficacy in r/r myeloma
-
5:25
how to optimize car-t therapy for all
-
4:05
risk factors to predict post-cd19 car-t cell therapy outcomes in patients with lbcl
-
1:12
status of the zuma-3 trial of car t-cell product kte-c19 for r/r all
-
1:35
key mechanisms of resistance to car t-cell therapy
-
1:57
tackling resistance to car-t in all
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
3:01
mechanisms of antigen escape following cd19-directed car-t therapy
-
2:43
mechanisms of resistance to car-t therapy in lymphoma & potential strategies to overcome these
-
1:48
managing crs and neurotoxicities associated with car-t in zuma-3
-
3:18
evaluating dual-targeting cd19/22 car-t cells in patients with r/r all
-
3:43
safety and efficacy of rapcabtagene autoleucel (ytb323), a car t-cell therapy, in r/r dlbcl